Therapeutic Group

Indication Dosage

Sunitinib is a medication used to treat certain types of cancer. It is commonly prescribed for the treatment of gastrointestinal stromal tumors (GISTs) and advanced kidney cancer (renal cell carcinoma). Sunitinib works by inhibiting the growth and spread of cancer cells in the body, thereby helping to slow down the progression of these malignancies.

Treatment Of Advanced Or Metastatic Renal Cell Carcinoma. Treatment Of Unresectable Or Metastatic Gastrointestinal Stromal Tumours (gist). Treatment Of Unresectable Or Metastatic Malignantgastro-intestinal Stromal Tumours, After Failure Ofimatinib, Treatment Of Advanced Or Metastatic Renal Cell Carcinoma: 

• Adult: 50 Mg Once Daily For 4 Weeks, Followed By a week Treatment-free Period To Complete a 6-week cycle, Adjusted In Steps Of 12.5 Mg, Doses Adjusted according To Tolerability; Usual Dose 25-75 Mg Daily 

Treatment Of Unresectable Or Metastatic Pancreatic Neuroendocrine Tumours: 

• Adult: 37.5 Mg Once Daily Without Treatment-free Period; Adjusted In Steps Of 12.5 Mg, Doses Adjusted According To Tolerability; Maximum 50 Mg Per Day

Content

Pregnancy

Positive Evidence Of Risk: Avoid

Stability

Contra Indications

Precautions

Lactation

Side Effects